drugset
drugset / Trial / NCT06057194

Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

NCT06057194 ↗

Phase 2 Not yet recruiting 90 enrolled Maimónides Biomedical Research Institute of Córdoba MERCK SHARP & DOHME DE ESPAÑA S.A. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease."

Timeline

Start
2023-10
Primary completion
2027-04
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Letermovir Small molecule 240 mg Oral

Indications

cytomegalovirus infection